Exavir Therapeutics Receives $3M Award from NIH / NIAID to Advance Ultra-Long-Acting Integrase Inhibitor XVIR-110
22 Aug 2023
Clinical Study
SAN FRANCISCO--(BUSINESS WIRE)-- Exavir Therapeutics, a company dedicated to transforming the lives of patients with chronic viral infections and CNS disorders with ultra-long-acting therapeutics, today announced that the company has received a $3M award from the National Institute of Allergy & Infectious Diseases (NIAID), a division of the National Institute of Health (NIH), to support the development of XVIR-110.
XVIR-110 is an ultra-long-acting HIV integrase inhibitorHIV integrase inhibitor with a preclinical pro suggests best-in-class potential for HIV pre-exposure prophylaxis (PrEP), and for HIV treatment as the cornerstone of a next-generation multi-drug regimen.
“We are thankful for the NIH’s support of American companies and innovative biotechnology, particularly in an area like HIV / AIDS that affects so many millions of people worldwide,” said Alborz Yazdi, co-founder and CEO of Exavir. “This award speaks to XVIR-110’s transformative potential, but also the importance of American agencies and public-private partnerships in improving population health outcomes. We look forward to filing our IND in short order to mark our transition to a clinical-stage company, and to fighting for our mission of transforming the lives of patients with chronic disease using ultra-long-acting medicines.”
“XVIR-110 has demonstrated ultra-long-acting pharmacokinetics in preclinical models, appropriate for dosing as infrequently as once-every-six-months or longer,” said Mark Cockett, Chief Scientific Advisor to Exavir. “This agent shows attenuated injection site reactions compared to commercially available Q2M cabotegravir in head-to-head animal studies, and also avoids drug-drug-interactions due to CYP3A and other mechanisms that may be present with investigational capsid inhibitors or ‘third-generation’ INSTIs and could limit the potential for use in a broad patient population.”
“This award is a testament to the strength of the data package in hand for our ultra-long-acting HIV integrase inhibitorHIV integrase inhibitor,” said Brian Kearney, Chief Scientific Officer at Exavir. “The support of the NIH will catalyze our mission to rapidly advance XVIR-110 into development as the first Q6M+ INSTI, and the only ultra-long-acting agent with the potential clinical pro widespread adoption by a broad group of patients with unmet medical need.”
About Exavir Therapeutics, Inc.
Exavir Therapeutics is a San Francisco, CA-based biotechnology company dedicated to developing transformative ultra-long-acting therapeutics for patients with chronic viral infections and central nervous system disorders.
HIV is one of the world's most serious public health challenges: it is estimated that there are more than 37 million people living with HIV worldwide, nearly 1.2 million people living with HIV in the United States alone. Approximately $30 billion is spent annually on HIV antiretroviral drugs worldwide.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Targets
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.